Compare DuPont de Nemours Inc (DD) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Eli Lilly And Co — how do they compare? DuPont de Nemours Inc trades at $131.75 (market cap $17.70B), while Eli Lilly And Co trades at $1,166.6 (market cap $1.06T). The key difference: Eli Lilly And Co is far larger — about 59.9× DuPont de Nemours Inc's market cap, and DuPont de Nemours Inc pays the higher dividend (1.83%). Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and Eli Lilly And Co for 93 Days on average.
| DD | LLY | |
|---|---|---|
Market Cap | $17.70B | $1.06T |
Volume | 638,303 | 2,297,239 |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $1.28K |
52-Week Low | $92.49 | $799.57 |
Typical Hold Time | 89 Days | 93 Days |
Enterprise Value | $19.09B | $1.11T |
Dividend Yield | 1.83% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $132.48, down 0.6% for the day, with neutral technical signals and mixed fundamentals. The company has beaten earnings estimates for three consecutive quarters but shows declining revenue and negative net income for 2025. Recent innovations include digital tools for sugar separation and sustainable Tyvek materials, while facing legal settlements over PFAS contamination.
Outlook remains cautious with analyst consensus favoring Buy (58.5%) but a price target of $95 below current levels. Key opportunities include margin expansion in healthcare and water technologies, while risks involve ongoing litigation costs, uneven construction demand, and profitability challenges despite recent earnings beats.
Eli Lilly (LLY) trades at $1,169.93, up 1.07% on the day, with a bullish technical signal and strong fundamental momentum. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 exceeding the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights promising pipeline updates in weight-loss and diabetes drugs, reinforcing growth prospects.
Outlook remains favorable given dominant market position and innovation pipeline, though high valuation multiples pose a risk. Analyst consensus is strongly bullish with a $1,340 price target. Key risks include competitive pressures and execution challenges in scaling production to meet demand for blockbuster therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
